Risankizumab Beats Ustekinumab for Previously Treated Crohn's

(MedPage Today) -- Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis factor (TNF) inhibitor, the...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news